Pacific Biosciences of California (PACB) News Today

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down to $2.04

Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold rating and eight have given a buy rati

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.87

Pacific Biosciences of California (NASDAQ:PACB) Trading 10.1% Higher

Bank of New York Mellon Corp cut its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 12.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,935,171 shares of the biotechnology

Koss Olinger Consulting LLC bought a new stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 800,000 shares of the biotech

Scotiabank cut their price objective on Pacific Biosciences of California from $8.00 to $7.00 and set a "sector outperform" rating on the stock in a report on Wednesday.

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating a

Assenagon Asset Management S.A. bought a new position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,295,303 shares of the biotechnology compa

Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) insider Jeff Eidel sold 26,760 shares of Pacific Biosciences of California stock in a transaction on Monday, August 19th. The shares were sold at an average price of $1.59, for a total value of $42,548.40. Following the transaction, the insider now owns 869,730 shares of the company's stock, valued at approximately $1,382,870.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

StockNews.com upgraded shares of Pacific Biosciences of California to a "sell" rating in a research report on Tuesday.

Morgan Stanley decreased their target price on Pacific Biosciences of California from $4.00 to $2.00 and set an "equal weight" rating for the company in a research note on Monday.

Cantor Fitzgerald reissued an "overweight" rating and set a $3.50 price target on shares of Pacific Biosciences of California in a research note on Thursday.

Price T Rowe Associates Inc. MD trimmed its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 45.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,955,382 shares of the bi

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and e

Pacific Biosciences of California (NASDAQ:PACB) will be releasing earnings after the market closes on Wednesday, August 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=320304)

Pacific Biosciences of California (NASDAQ:PACB) Shares Down 5.2%

Bellevue Group AG decreased its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 37.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,592,251 shares of the biotechnology company's st

Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 4.4%

Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 3.9%

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down to $2.17

Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 21.9%

Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.

BNP Paribas Financial Markets lifted its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 100.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,167,708 shares of the biotechno

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fifteen brokerages that are currently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a hold rating and eigh

Vanguard Group Inc. increased its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 15.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,789,552 shares of the biotec

StockNews.com raised Pacific Biosciences of California to a "sell" rating in a report on Wednesday.

Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.8%

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.82